Skip to Content
  • Article
  • Open Access

26 March 2024

11 Pages

Repurposing the Fibrosis-4 Score in Rheumatoid Arthritis: Data from the ESPOIR Cohort

,
,
,
,
,
,
,
,
…
1
National Reference Center for Rare Auto-Immune Diseasesest Sud-Ouest (RESO), Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, 67091 Strasbourg, France
2
Department of Public Health, Hôpitaux Universitaires de Strasbourg, 67091 Strasbourg, France
3
Department of Rheumatology, INSERM, AP-HP Saint-Antoine Hospital, Sorbonne University, 75005 Paris, France
4
Faculty of Medicine, Montpellier University, 34090 Montpellier, France
This article belongs to the Section Immunology & Rheumatology

Abstract

Background: We aimed to evaluate the value of the Fibrosis-4 (FIB-4) score as a prognostic factor in RA in the prospective ESPOIR cohort. Methods: We included patients from the ESPOIR cohort with a diagnosis of RA according to ACR/EULAR criteria. The formula for the FIB-4 score is as follows: [age (years) × aspartate transaminase level (U/L)]/[platelet count (109/L) × alanine aminotransferase level (U/L)1/2]. We used a linear mixed-effects model with a random effect of patient to account for repeated measures over time. Results: Overall, 647 of the 813 patients included met the ACR/EULAR criteria for RA, with no differential diagnosis during the first 10 years of follow-up. Of these patients, at baseline, 633 had a calculable FIB-4 score. Median FIB-4 score was 0.75 (interquartile range 0.53–0.99). On multivariate analysis, FIB-4 score was not independently associated with progression of Disease Activity Score in 28 joints over 10 years of follow-up, unlike baseline C-reactive protein level and SJC. Baseline FIB-4 score was not associated with the modified Sharp score at 5-year follow-up, unlike age and ACPAs. FIB-4 score was not associated with mortality (hazard ratio 1.1 [95% CI 0.46; 2.8], p = 0.77) or major adverse cardiovascular events (0.46 [0.13; 1.6], p = 0.22) over the 10-year follow-up. No significant change in FIB-4 score over time was related to treatments. Conclusions: The present prospective cohort study did not find a prognostic role of FIB-4 score in RA. Reassuringly, FIB-4 score was not increased with DMARD treatment after 10 years of follow-up.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.